Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline
Q1 2021 Net Product Revenues of $1.9M, a 100% increase over Q4 2020
Achieved payor coverage of MYCAPSSA for over 185 million lives
Submitted an Investigational New Drug (IND) application for the study of MYCAPSSA in patients with carcinoid syndrome associated with Neuroendocrine Tumors (NET)
https://finance.yahoo.com/news/chiasma-reports-first-quarter-financial-110500019.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.